Liprolog Mix50

Insulin lispro, the active ingredient in Liprolog Mix50, is an insulin analog presented as a subcutaneous injectable formulation for rapid‑acting insulin therapy. It is used to lower blood glucose in patients with diabetes mellitus, including both type 1 and type 2 disease, and provides a rapid onset of action to manage post‑prandial glucose spikes.

GNH USA supplies Liprolog Mix50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through regulated distribution channels. The company adheres to EU quality standards and provides comprehensive logistics support for temperature‑sensitive products.

Insulin lispro is a rapid‑acting insulin analog that lowers blood glucose by facilitating cellular uptake.

- Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces basal insulin requirements. - Type 2 diabetes mellitus: used as a mealtime insulin to achieve tighter glycemic control. - Insulin pump therapy: provides rapid‑acting insulin for continuous subcutaneous infusion in pump‑based regimens. - Gestational diabetes mellitus: may be prescribed when rapid insulin action is needed during pregnancy.

Insulin lispro may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with chronic use. - Lipodystrophy: localized changes in fat tissue at repeated injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: seizures or loss of consciousness requiring immediate assistance. - Allergic reaction: urticaria, angioedema, or anaphylaxis needing emergency treatment. - Insulin edema: fluid retention leading to peripheral swelling.

When using insulin lispro, several precautions should be observed to ensure safe and effective therapy. - Dose adjustment: tailor the dose to carbohydrate intake, physical activity, and blood glucose monitoring results. - Renal impairment: monitor closely for hypoglycemia as insulin clearance may be reduced. - Elderly patients: start with lower doses and titrate slowly due to increased sensitivity. - Pregnancy: use only if the anticipated benefit justifies the potential risk to the fetus. - Hypoglycemia risk: educate patients on recognizing symptoms and appropriate treatment measures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with other medicines, altering its glucose‑lowering effect or increasing adverse event risk.

Major Interactions (Avoid): - Concurrent sulfonylureas: additive hypoglycemic effect may lead to severe low blood sugar. - Beta‑blockers: can mask typical hypoglycemia symptoms such as tachycardia. - MAO inhibitors: may potentiate insulin’s glucose‑lowering action, increasing hypoglycemia risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: can raise blood glucose levels, potentially reducing insulin effectiveness. - Systemic corticosteroids: increase insulin requirements due to hyperglycemic effect.